Aptahem AB (publ)
Stockholm Stock Exchange APTA.ST
Aptahem AB (publ) Revenue for the year ending December 31, 2023: USD 259.64 K
Aptahem AB (publ) Revenue is USD 259.64 K for the year ending December 31, 2023, a 0.00% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
-
Aptahem AB (publ) Revenue for the year ending December 31, 2022 was USD 0.00, a 0.00% change year over year.
-
Aptahem AB (publ) Revenue for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
-
Aptahem AB (publ) Revenue for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
-
Aptahem AB (publ) Revenue for the year ending December 31, 2019 was USD 0.00, a -100.00% change year over year.
Key data
| Date | Revenue | Gross Profit | Operating Income | EBIT |
|---|
Market news
Loading...
Stockholm Stock Exchange: APTA.ST
| CEO | Mr. Mikael Lindstam |
| IPO Date | April 17, 2015 |
| Location | Sweden |
| Headquarters | Norra Vallgatan 58, 4TR |
| Employees | 5 |
| Sector | Health Care |
| Industries | |
Description
Aptahem AB (publ), a clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in preclinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children's Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email